PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Byoung Chul Cho(Yonsei University), Benjamin Besse(Institut Gustave Roussy), Kōichi Goto(National Cancer Center Hospital East), Benjamin Solomon(Peter MacCallum Cancer Centre), Sang‐We Kim(Ulsan College), Denise Trone(Unknown), Sanjay Popat(Royal Marsden NHS Foundation Trust), Rafał Dziadziuszko(Gdańsk Medical University), Minal Mehta(Millennium Engineering and Integration (United States)), Adrianus J. de Langen(The Netherlands Cancer Institute), Parneet Cheema(University of Toronto), Misako Nagasaka(University of California, Irvine), Felipe Ades(Bristol-Myers Squibb (United States)), Vamsidhar Velcheti(Cleveland Clinic), C. Calvet(Bristol-Myers Squibb (United States)), Nong Yang(Central South University), Shanna Stopatschinskaja(Bristol-Myers Squibb (Belgium)), D. Ross Camidge(University of Colorado Denver), W. Marston Linehan(Harvard University), Enriqueta Felip(Institut Català d'Ornitologia), Jürgen Wolf(University of Cologne), Shun Lu(Shanghai Chest Hospital), Ki Hyeong Lee(Chungbuk National University Hospital), Steven Kao(Chris O’Brien Lifehouse), Christoph Springfeld(Heidelberg University)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k